Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1257MR)

This product GTTS-WQ1257MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1257MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5661MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ8689MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ2271MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ3231MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ10063MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ7271MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ3248MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ554MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 4D5-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW